CDCD163P: A Protein as A Potential Drug Target and Biomarker (G126661)

Target Name: CCDC163

NCBI ID: G126661

CCDC163

CDCD163P: A Protein as A Potential Drug Target and Biomarker

CCDC163 (CCDC163P) is a protein that is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the C-type water-type cytoskeleton protein (Cytoskeleton-associated protein 163) family, which is characterized by the presence of a unique N-terminal hypervariable region (HVR1) and a C-terminal alpha-helical domain.

CCDC163P is a 19 kDa protein that is expressed in the brain, pancreas, and gastrointestinal tract, and is also found in various other tissues, including muscle, heart, liver, and kidney. It is predominantly localized to the endoplasmic reticulum (ER), a protein synthesis and quality control organelle that is responsible for retrieving and modifying proteins before they are transported to the cytoplasm for further processing or degradation.

One of the unique features of CCDC163P is its ability to interact with various signaling molecules, including insulin, growth factors, and cytokines. This interaction allows CCDC163P to regulate various cellular processes, including cell adhesion, migration, and survival.

In addition to its role in signaling pathways, CCDC163P is also recognized as a potential drug target. Its expression has been associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The ability of CCDC163P to interact with insulin has led to its potential as a drug target for the treatment of type 1 diabetes. Insulin is a key signaling molecule in the development and progression of type 1 diabetes, and its production is regulated by various factors, including CCDC163P.

Research has shown that individuals with type 1 diabetes have lower levels of CCDC163P in their pancreatic beta cells compared to healthy individuals. This suggests that targeting CCDC163P with a drug that can increase its expression in pancreatic beta cells may be a promising strategy for the treatment of type 1 diabetes.

Another potential drug target for CCDC163P is its role in cell adhesion and migration. CCDC163P has been shown to be involved in the regulation of cell-cell adhesion and has been implicated in various diseases, including cancer.

The ability of CCDC163P to regulate cell migration is also a potential drug target in neurodegenerative diseases. CCDC163P has been shown to be involved in the regulation of neural cell migration and has been linked to the development of neurodegenerative diseases.

In addition to its potential as a drug target, CCDC163P is also recognized as a potential biomarker for various diseases. Its expression has been associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The identification of CCDC163P as a potential drug target and biomarker has led to a growing body of research aimed at understanding its role in various diseases. Further studies are needed to determine the exact mechanisms by which CCDC163P is involved in these diseases and to develop effective treatments.

In conclusion, CCDC163P is a protein that has been identified as a potential drug target and biomarker in a variety of diseases. Its unique ability to interact with various signaling molecules and its expression in various tissues make it an attractive target for further research and development. Further studies are needed to fully understand its role in these diseases and to develop effective treatments.

Protein Name: CCDC163 Homolog

The "CCDC163 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC163 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets